+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mental Disorders Drugs Market Research Reports

Anorexia - Pipeline Insight, 2024 - Product Thumbnail Image

Anorexia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Schizoaffective Disorder - Pipeline Insight, 2024 - Product Thumbnail Image

Schizoaffective Disorder - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Borderline Personality Disorders - Pipeline Insight, 2024 - Product Thumbnail Image

Borderline Personality Disorders - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Cannabis-Induced Psychosis (CIP) - Pipeline Insight, 2024 - Product Thumbnail Image

Cannabis-Induced Psychosis (CIP) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Gender dysphoria - Pipeline Insight, 2024 - Product Thumbnail Image

Gender dysphoria - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Obese patients with Schizophrenia - Pipeline Insight, 2024 - Product Thumbnail Image

Obese patients with Schizophrenia - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Immune-Mediated Depression - Pipeline Insight, 2024 - Product Thumbnail Image

Immune-Mediated Depression - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Attention Deficit Hyperactivity Disorder - Pipeline Insight, 2024 - Product Thumbnail Image

Attention Deficit Hyperactivity Disorder - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Obsessive Compulsive Disorder - Pipeline Insight, 2024 - Product Thumbnail Image

Obsessive Compulsive Disorder - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Parkinson's disease psychosis - Pipeline Insight, 2024, - Product Thumbnail Image

Parkinson's disease psychosis - Pipeline Insight, 2024,

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Postpartum Depression - Pipeline Insight, 2024 - Product Thumbnail Image

Postpartum Depression - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Major Depressive Disorder - Pipeline Insight, 2024 - Product Thumbnail Image

Major Depressive Disorder - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 180 Pages
  • Global
From
Treatment Resistant Depression - Pipeline Insight, 2024 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Bipolar Depression - Pipeline Insight, 2024 - Product Thumbnail Image

Bipolar Depression - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Schizophrenia - Epidemiology Forecast - 2034 - Product Thumbnail Image

Schizophrenia - Epidemiology Forecast - 2034

  • Report
  • March 2024
  • 198 Pages
  • Global
From
Anorexia Nervosa - Pipeline Insight, 2024 - Product Thumbnail Image

Anorexia Nervosa - Pipeline Insight, 2024

  • Clinical Trials
  • February 2024
  • 60 Pages
  • Global
From
Serotonin receptor 2 angonist - Pipeline Insight, 2024 - Product Thumbnail Image

Serotonin receptor 2 angonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Sigma-1 receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Sigma-1 receptor agonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
mGlu 2/3/5 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

mGlu 2/3/5 Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2024 - Product Thumbnail Image

Serotonin Reuptake Inhibitor (SRI) - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Mental Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat mental health conditions. These drugs are used to treat a wide range of mental health issues, including depression, anxiety, bipolar disorder, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The market is highly competitive, with many companies vying for market share. The Mental Disorders Drugs market is driven by the increasing prevalence of mental health issues, as well as the growing demand for effective treatments. Additionally, advances in technology and research have enabled the development of more effective drugs. Some of the major players in the Mental Disorders Drugs market include Pfizer, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, and AstraZeneca. These companies are engaged in the development and production of drugs used to treat mental health conditions. Additionally, they are involved in research and development activities to develop new drugs and treatments. Show Less Read more